결핵 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 질환 유형별, 요법별, 투여 경로별, 제형별, 유통 채널별, 지역별, 경쟁(2021-2031년)

The Global Tuberculosis Therapeutics Market is projected to grow from USD 2.27 Billion in 2025 to USD 3.14 Billion by 2031, achieving a Compound Annual Growth Rate of 5.56%. This market focuses on the commercialization and distribution of pharmacological agents, including first-line and second-line antibiotics, for treating active and latent Mycobacterium tuberculosis infections. It is primarily propelled by the persistent global burden of multi-drug resistant strains and sustained financial commitments from international health organizations aimed at disease eradication, which establish a foundational demand and ensure stable procurement, especially in high-burden regions dominated by government purchasing.

Market Driver

The market is significantly driven by the increasing prevalence of Multi-Drug Resistant Tuberculosis (MDR-TB), which heightens the global demand for advanced second-line and combinatorial treatments as resistance to standard first-line antibiotics expands. For instance, the WHO reported 400,000 people developed MDR/RR-TB in 2023, compelling national health programs to acquire specialized regimens. Simultaneously, the introduction of shorter and more effective all-oral treatment regimens, such as BPaL (bedaquiline, pretomanid, and linezolid), is transforming clinical protocols and boosting the adoption of innovative therapies. The shift from lengthy, injectable courses to streamlined oral regimens markedly improves patient adherence and clinical success rates, leading to rapid uptake by healthcare authorities, with the global MDR/RR-TB treatment success rate rising to 68%. This widespread deployment is supported by organizations like the Global Fund, which treated a record 7.1 million people for tuberculosis in 2023, indicating substantial therapeutic volume requirements.

Market Challenge

However, the market's expansion is significantly hindered by chronic underfunding, which restricts national health programs' capacity to procure and distribute essential antibiotic regimens, disrupting supply chains and diminishing incentives for pharmaceutical companies to invest in novel therapeutics. This financial deficit results in a stagnant product pipeline, particularly affecting high-burden regions where dependence on external donor funding leads to reliance on older medications, as only US$ 5.7 billion was available for TB services in 2024, far short of global requirements. This persistent gap consequently limits the addressable market and revenue prospects for therapeutic developers.

Market Trends

Despite these challenges, the market is witnessing transformative trends, including innovation in pediatric-friendly dispersible fixed-dose combinations that offer precise, palatable formulations, improving adherence and bioavailability for young patients-a demographic with a record 700,000 children notified with TB in 2023. Additionally, the integration of Artificial Intelligence in anti-tubercular drug discovery is revolutionizing the R&D pipeline, with generative models and machine learning algorithms being leveraged to efficiently identify novel chemical entities and drug targets, thereby accelerating early-stage discovery and enabling the development of new antibiotic classes capable of circumventing existing resistance mechanisms, as demonstrated by successful initiatives using generative AI to identify promising compounds.

Key Market Players

• AstraZeneca PLC
• Johnson & Johnson Services, Inc.
• Eli Lilly and Company
• Mylan Inc.
• Teva Pharmaceutical Industries Ltd
• Sanofi S.A.
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Pfizer Inc.

Report Scope

In this report, the Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tuberculosis Therapeutics Market, By Disease Type

• Active TB
• Latent TB

Tuberculosis Therapeutics Market, By Therapy

• First-Line Therapy
• Second-Line Therapy

Tuberculosis Therapeutics Market, By Route of Administration

• Oral
• Parenteral
• Others

Tuberculosis Therapeutics Market, By Dosage Form

• Tablets
• Capsules
• Injection
• Others

Tuberculosis Therapeutics Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Tuberculosis Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tuberculosis Therapeutics Market.

Available Customizations:

Global Tuberculosis Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tuberculosis Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Active TB, Latent TB)
  • 5.2.2. By Therapy (First-Line Therapy, Second-Line Therapy)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Tuberculosis Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Therapy
  • 6.2.3. By Route of Administration
  • 6.2.4. By Dosage Form
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tuberculosis Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Therapy
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Dosage Form
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Tuberculosis Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Therapy
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Dosage Form
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Therapy
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Dosage Form
      • 6.3.3.2.5. By Distribution Channel

7. Europe Tuberculosis Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Therapy
  • 7.2.3. By Route of Administration
  • 7.2.4. By Dosage Form
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tuberculosis Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Therapy
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Dosage Form
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. France Tuberculosis Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Therapy
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Dosage Form
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. United Kingdom Tuberculosis Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Therapy
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Dosage Form
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. Italy Tuberculosis Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Therapy
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Dosage Form
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Tuberculosis Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Therapy
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Dosage Form
      • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Tuberculosis Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Therapy
  • 8.2.3. By Route of Administration
  • 8.2.4. By Dosage Form
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Tuberculosis Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Therapy
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Dosage Form
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Tuberculosis Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Therapy
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Dosage Form
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Tuberculosis Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Therapy
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Dosage Form
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Therapy
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Dosage Form
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Tuberculosis Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Therapy
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Dosage Form
      • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Tuberculosis Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Therapy
  • 9.2.3. By Route of Administration
  • 9.2.4. By Dosage Form
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Tuberculosis Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Therapy
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Dosage Form
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. UAE Tuberculosis Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Therapy
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Dosage Form
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. South Africa Tuberculosis Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Therapy
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Dosage Form
      • 9.3.3.2.5. By Distribution Channel

10. South America Tuberculosis Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Therapy
  • 10.2.3. By Route of Administration
  • 10.2.4. By Dosage Form
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Tuberculosis Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Therapy
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Dosage Form
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Colombia Tuberculosis Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Therapy
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Dosage Form
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. Argentina Tuberculosis Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Therapy
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Dosage Form
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Tuberculosis Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Johnson & Johnson Services, Inc.
• 15.3. Eli Lilly and Company
• 15.4. Mylan Inc.
• 15.5. Teva Pharmaceutical Industries Ltd
• 15.6. Sanofi S.A.
• 15.7. Novartis AG
• 15.8. Sun Pharmaceutical Industries Ltd
• 15.9. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer